ABSCIENCES (EPA:AB) AB Science announced the continuation of the Phase 2 study evaluating masitinib in combination with isoquercetin in COVID-19, following the recommendation of the Data and Safety Monitoring Board (DSMB)
Transparency directive : regulatory news
28/04/2022 08:01